Title: 1419 - In situ Evaluation of Acrylic Resin Containing Chlorhexidine


Caroline Maluf (Presenter)
Rio de Janeiro State University

Guilherme de Oliveira, Rio de Janeiro State University
Marcela Michelon, Rio de Janeiro State University
Marcelino dos Anjos, Rio de Janeiro State University
Raphael Hirata Junior, Rio de Janeiro State University
Eduardo Lourenço, Rio de Janeiro State University
Daniel Telles, Rio de Janeiro State University


Objectives: The objective of the present study, considering the importance of biofilm control in teeth or implants, was to evaluate in situ the influence of incorporation of chlorhexidine diacetate (CDA) in acrylic resins based on PMMA.

Methods: Firstly, 32 volunteers were selected, all of whom used an intraoral device that contained specimens without and with chlorhexidine (1%) over the course of 24 hours. After that, the microbial adhesion to both materials’ surface was measured by the plate count. The samples were plated in triplicate in the following culture mediums: Blood agar to evaluate the total number of bacteria (aerobic bacteria) and Mitis salivarius agar containing 0.25 units of bacitracin/mL plus 20% sucrose, to determine Mutans Streptococci. In addition, biofilm morphological differences were also observed in the scanning electron microscopy of the control acrylic resin versus the acrylic resin incorporating CDA. Finally, the chemical composition of the test specimens were tested using X-ray fluorescence

Results: The results showed that the antimicrobial effect did not differ between the control acrylic resin and acrylic resin incorporating CDA (p>0.05). Furthermore, the presence of the chlorhexidine was detected before and after the insertion of the specimens with CDA in the oral cavity.

Conclusions: It was concluded that the presence of the drug in the acrylic resin after 24 hours was verified. However, no results were found to confirm the presence of an antimicrobial potential of the drug at the concentrations used in situ specimens.

Disclosure Statement:
The submitter must disclose the names of the organizations with which any author have a relationship, the nature of the relationship, and the clinical or research area involved. The following is submitted: NONE